BSE Live
Sep 30, 12:36Prev. Close
5407.20
Open Price
5460.00
Bid Price (Qty.)
5408.40 (8)
Offer Price (Qty.)
5415.25 (4)
NSE Live
Sep 30, 12:36Prev. Close
5409.00
Open Price
5457.00
Bid Price (Qty.)
5411.00 (2)
Offer Price (Qty.)
5412.50 (8)
Key Financial Ratios of Alkem Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
Per Share Ratios | ||||||
Basic EPS (Rs.) | 190.77 | 146.13 | 94.88 | 128.90 | 140.93 | |
Diluted EPS (Rs.) | 190.77 | 146.13 | 94.88 | 128.90 | 140.93 | |
Cash EPS (Rs.) | 214.51 | 166.58 | 114.12 | 147.24 | 157.59 | |
Book Value [ExclRevalReserve]/Share (Rs.) | 1,030.68 | 882.86 | 782.09 | 731.38 | 637.87 | |
Book Value [InclRevalReserve]/Share (Rs.) | 1,030.68 | 882.86 | 782.09 | 731.38 | 637.87 | |
Dividend / Share(Rs.) | 45.00 | 40.00 | 50.00 | 34.00 | 30.00 | |
Revenue from Operations/Share (Rs.) | 737.22 | 815.37 | 757.39 | 738.59 | 603.90 | |
PBDIT/Share (Rs.) | 222.77 | 189.97 | 137.45 | 168.15 | 178.92 | |
PBIT/Share (Rs.) | 199.05 | 169.53 | 118.23 | 149.83 | 162.28 | |
PBT/Share (Rs.) | 192.68 | 157.34 | 111.00 | 146.66 | 157.62 | |
Net Profit/Share (Rs.) | 190.79 | 146.14 | 94.90 | 128.92 | 140.95 | |
Profitability Ratios | ||||||
PBDIT Margin (%) | 30.21 | 23.29 | 18.14 | 22.76 | 29.62 | |
PBIT Margin (%) | 27.00 | 20.79 | 15.60 | 20.28 | 26.87 | |
PBT Margin (%) | 26.13 | 19.29 | 14.65 | 19.85 | 26.09 | |
Net Profit Margin (%) | 25.87 | 17.92 | 12.52 | 17.45 | 23.34 | |
Return on Networth / Equity (%) | 18.51 | 16.55 | 12.13 | 17.62 | 22.09 | |
Return on Capital Employed (%) | 18.68 | 18.54 | 14.59 | 19.80 | 24.67 | |
Return on Assets (%) | 14.62 | 12.44 | 8.91 | 11.70 | 15.64 | |
Total Debt/Equity (X) | 0.03 | 0.09 | 0.12 | 0.26 | 0.18 | |
Asset Turnover Ratio (%) | 0.59 | 0.73 | 0.70 | 0.74 | 67.01 | |
Liquidity Ratios | ||||||
Current Ratio (X) | 2.92 | 2.59 | 2.22 | 1.66 | 1.94 | |
Quick Ratio (X) | 2.39 | 1.99 | 1.66 | 1.18 | 1.42 | |
Inventory Turnover Ratio (X) | 5.23 | 1.54 | 1.42 | 1.63 | 4.77 | |
Dividend Payout Ratio (NP) (%) | 22.01 | 30.79 | 46.37 | 27.15 | 19.86 | |
Dividend Payout Ratio (CP) (%) | 19.58 | 27.01 | 38.56 | 23.77 | 17.76 | |
Earnings Retention Ratio (%) | 77.99 | 69.21 | 53.63 | 72.85 | 80.14 | |
Cash Earnings Retention Ratio (%) | 80.42 | 72.99 | 61.44 | 76.23 | 82.24 | |
Valuation Ratios | ||||||
Enterprise Value (Cr.) | 57,655.53 | 58,951.47 | 39,583.32 | 43,190.74 | 32,807.45 | |
EV/Net Operating Revenue (X) | 6.54 | 6.05 | 4.37 | 4.89 | 4.54 | |
EV/EBITDA (X) | 21.65 | 25.96 | 24.09 | 21.49 | 15.34 | |
MarketCap/Net Operating Revenue (X) | 6.62 | 6.06 | 4.49 | 4.90 | 4.59 | |
Retention Ratios (%) | 77.98 | 69.20 | 53.62 | 72.84 | 80.13 | |
Price/BV (X) | 4.73 | 5.60 | 4.34 | 4.95 | 4.35 | |
Price/Net Operating Revenue | 6.62 | 6.06 | 4.49 | 4.90 | 4.59 | |
Earnings Yield | 0.04 | 0.03 | 0.03 | 0.04 | 0.05 |
29.09.2025
23.09.2025
19.09.2025
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.06.2025
Alkem Lab Standalone March 2025 Net Sales at Rs 2,044.94 crore, down 13.55% Y-o-Y
05.06.2025
Alkem Lab Consolidated March 2025 Net Sales at Rs 3,143.75 crore, up 7.08% Y-o-Y
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key